Stereotactic laser ablation technology to treat brain tumors

Robert CRennert of neurosurgery at the University of California Hospital in San Diego, USA, conducted a multicenter, exploratory clinical study of laser ablation of abnormal neurotissue lesions in neurotic disease using the NeuroBlate System robotics (Laser Ablation of Abnormal Tissue Robotic Syd) (LAANTERN) in the August 2018 issue of World Neurosurgery- Excerpted from the article chapter
.Ref: Rennert RC, et alWorld Neurosurg2018 Aug;116:e566-e570.doi: 10.1016/j.wneu.2018.05.039.Epub 2018 May 14stereoscopic directional laser ablation (stereoscopic directional laser ablation) Lasertactic ablation, SLA) is a new minimally invasive neurosurgery technique that uses laser thermal effects to selectively destroy targets, including directional insertion of laser probes into target areas, activation and release of laser beams, inducing thermal effects to degenerate target tissue proteins, cell membrane dissolution, and cell solidification necrosisUnder MRI temperature monitoring, the thermal effect range can be controlled to minimize damage to the surrounding normal brain tissueDue to minimalalization and controllable, there are unique advantages in the treatment of lesions that cannot reach the lesions in the routine surgeryRobert CRennert of neurosurgery at the University of California Hospital in San Diego, USA, conducted a multicenter, exploratory clinical study of laser ablation of abnormal neurotissue lesions in neurotic disease using the NeuroBlate System robotics (Laser Ablation of Abnormal Tissue Robotic Syd) (LAANTERN) in the August 2018 issue of World Neurosurgerystudy included 100 cases (of which 42 were male and 58 female) patients with intracranial lesions treated with SLA, and 100 cases were collected for pre-study treatment in LAANTERN as a control group for statistical analysisThe vast majority of patients are high-level gliomas and brain metastatic tumors; In patients with high levels of glioma, The proportion of SLA used for primary or recurrent tumors was 45% to 55% (P-0.54)Of patients with brain metastasis, 91% used SLA for lesions that failed radiation therapy or radiation therapy, while only 9% of patients used SLA as pre-treatment for newly diagnosed encephalopathy (P 0.001)46% of the lesions were in the frontal lobe, 19% of the top lobe, 20% temporal lobe, 3% pillow leaves, 2% cerebellum, 5% clotyces and other deep nuclear groups and 5% in the stoic, of which 46% of the sLA treatment sprees were deeper (Figure 1)45% of lesions, SLA directly in place of surgical removal, 43% due to surgical removal difficulties and choose SLA surgeryFigure 1 The intracranial lesions treated by stereotactic laser ablation techniques: 46% of the treated lesions are located in the deep, usually not surgically accessible, and 40% of the lesions are in shallow , high-level gliomas and brain metastasis are the main sLA adaptations in LAANTERN studies For high-level gliomas, SLA can be used to treat patients who are first or relapsed For brain metastasis, SLA is commonly used for relapsed lesions SLA can replace surgery to treat some superficial brain tumors, while SLA has the advantage of treating lesions that are difficult to reach for classic surgery.